Equillium to Present at Two Upcoming Investor Conferences
11/09/2021 - 08:00 AM
LA JOLLA, Calif. --(BUSINESS WIRE)--
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will participate in fireside chat presentations at the Stifel 2021 Virtual Healthcare Conference and the Jefferies Virtual London Healthcare Conference .
Management will provide a high-level overview of itolizumab’s mechanism of action and review each of Equillium’s ongoing clinical programs, as well as data recently presented at ACR, ASN & ACAAI. Members of Equillium’s leadership team will be available for one-on-one meetings during both conferences.
Conference:
Stifel 2021 Virtual Healthcare Conference
Location:
Live Virtual Webcast on corporate website
Date:
Tuesday, November 16, 2021
Time:
12:20 PM Pacific Time | 3:20 PM Pacific Time
Conference:
Jefferies Virtual London Healthcare Conference
Location:
Recorded Virtual Webcast on corporate website
Date:
Thursday, November 18, 2021
Time:
12:00 AM Pacific Time | 3:00 AM Eastern Time
Webcast access for both presentations will be available on the “Events & Presentations” section of the Company’s website at https://ir.equilliumbio.com/events-and-presentations . An archived replay of both conferences will be available for 90 days.
About Equillium
Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma.
For more information, visit www.equilliumbio.com .
View source version on businesswire.com : https://www.businesswire.com/news/home/20211109005733/en/
Investor Contact
Michael Moore
ir@equilliumbio.com
Media Contacts
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
Source: Equillium, Inc.
EQ Rankings
#5167 Ranked by Stock Gains
EQ Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
La Jolla
About EQ
equillium, inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor cd6, which is in phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and phase 1 clinical trial for the treatment of asthma and lupus nephritis. the company was formerly known as attenuate biopharmaceuticals, inc. and changed its name to equillium, inc. in may 2017. equillium, inc. was founded in 2017 and is headquartered in la jolla, california.
